Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

Multiple Myeloma Clinical Trial

— MASTER-2  

Official title:

MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05231629
• Other study ID #: UAB-21107
• Status: Recruiting
• Phase: Phase 2
• Start date: December 13, 2023
• Est. completion date: December 2027

Study information

• Verified date: December 2023
• Source: University of Alabama at Birmingham
• Contact: Pamela Hardwick, RN
• Phone: 205-975-5387
• Email: pamdixon[@]uab.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow.

For patients who become MRD "negative" (i.e. less than 1 cancer cell out of 100,000) at the end of 6 cycles of therapy, this study will study if that good response can be maintained with 3 additional cycles of treatment instead of use of autologous hematopoietic cell transplantation (AHCT).

For patients who are MRD "positive" at the end of 6 cycles of therapy, this study will answer whether more patients can become and remain MRD "negative" with AHCT plus teclistamab in combination with daratumumab when compared with patients who undergo AHCT followed by lenalidomide (an established anti-myeloma drug) plus daratumumab.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 2027
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age>18 years with no upper age limit

2. Newly diagnosed multiple myeloma with indication for initiation of therapy.

3. ECOG performance status 0-2

4. No prior MM-directed therapy except for dexamethasone (up to 160 mg) and/or bortezomib (up to 5.2 mg/m2) and/or cyclophosphamide up to 1000 mg/m2 and/or lenalidomide (up to 21 days of therapy) administered for no longer than 4 weeks prior to enrollment (pre induction). If subject received any prior therapy, pretreatment parameters necessary for disease characterization and response assessment must be available.

5. Measurable disease meeting at least one of the following criteria (at screening or prior to pre induction):

1. Serum monoclonal (M) protein =1.0 g/dl (=0.5 g/dl if IgA, IgD, IgE or IgM multiple myeloma)

2. = 200 mg of M protein/24h in the urine

3. Difference between affected and unaffected free light chain =10 mg/dL with abnormal kappa to lambda ratio.

6. Have clinical laboratory values meeting the following criteria during the Screening Phase and also at start of administration of study treatment

1. Hemoglobin =7 g/dL (=4.65 mmol/L; without prior RBC transfusion within 7 days before the laboratory test; recombinant human erythropoietin use is permitted)

2. Platelets =75×10^9/L in participants in whom <50% of bone marrow nucleated cells are plasma cells and =50×10^9/L in participants in whom

• 50% of bone marrow nucleated cells are plasma cells (without transfusion support or thrombopoietin receptor agonist within 7 days before the laboratory test)

3. Absolute neutrophil count =1.0×109/L (prior growth factor support is permitted but must be without support for 7 days for G-CSF or GM-CSF and for 14 days for pegylated G CSF)

4. AST and ALT =2.5×ULN

5. eGFR =30 mL/min based on Modified Diet in Renal Disease Formula calculation or creatine clearance measured by a 24-hour urine collection

6. Total bilirubin =2.0×ULN; except in participants with congenital bilirubinemia, such as Gilbert syndrome (in which case direct bilirubin =1.5×ULN is required)

7. Serum calcium corrected for albumin =14 mg/dL (=3.5 mmol/L) or free ionized calcium =6.5 mg/dL (=1.6 mmol/L)

7. A woman of childbearing potential must have a negative highly-sensitive serum pregnancy test at screening and again within 24 hours of the start of study treatment and must agree to further serum or urine pregnancy tests during the study

8. A woman must be

1. Not of childbearing potential, or

2. Of childbearing potential and

1. Practicing true abstinence; or

2. Have a sole partner who is vasectomized; or

3. Practicing =1 highly-effective, user-independent method of contraception

9. A woman must agree not to donate eggs (ova, oocytes) or freeze for future use, for the purposes of assisted reproduction during the study and for 90 days after receiving the last dose of study treatment

10. A man must wear a condom (with or without spermicidal foam/gel/film/cream/suppository) when engaging in any activity that allows for passage of ejaculate to another person during the study and for a minimum of 90 days after receiving the last dose of study treatment. If a female partner is of childbearing potential, she must also be practicing a highly effective method of contraception

11. A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose of study treatment.

12. Must be willing and able to adhere to the lifestyle restrictions specified in this protocol

13. Must sign an ICF (or their legally acceptable representative must sign) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study.

14. All participants must agree to comply with and be enrolled in Revlimid REMSTM program.

15. All participants must meet institution-specific criteria for AHCT eligibility as assessed by the investigator.

16. In line with the higher incidence of MM in Blacks, and to address the historical underrepresentation of ethnical minorities in MM trials, at least 25% of the enrolled patients will be of ethnical minorities.

Exclusion Criteria:

1. Diagnosis of Plasma cell leukemia, primary light chain amyloidosis, POEMS, or Waldenstrom's macroglobulinemia.

2. Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients (refer to the teclistamab Investigator's Brochure and appropriate package inserts)

3. Prior or concurrent exposure to any of the following:

1. Teclistamab or any anti-BCMA therapy

2. Daratumumab or any anti-CD38 therapy

3. Targeted therapy, epigenetic therapy, or treatment with an investigational drug or an invasive investigational medical device within 21 days or =5 half-lives, whichever is less

4. Investigational vaccine within 4 weeks

5. Live, attenuated vaccine within 4 weeks before randomization.

6. Radiotherapy within 14 days or focal radiation within 7 days

7. Gene-modified adoptive cell therapy (eg, chimeric antigen receptor modified T cells, NK cells) within 3 months

8. Cytotoxic therapy within 14 days

9. PI therapy within 14 days

10. IMiD agent therapy within 14 days

4. Known active CNS involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain MRI and lumbar cytology are required.

5. Myelodysplastic syndrome or active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than multiple myeloma. The only allowed exceptions are:

1. Non-muscle invasive bladder cancer treated within the last 24 months that is considered completely cured

2. Skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured.

3. Noninvasive cervical cancer treated within the last 24 months that is considered completely cured

4. Localized prostate cancer (N0M0):

1. With a Gleason score of =6, treated within the last 24 months, or untreated and under surveillance

2. With a Gleason score of 3+4 that has been treated >6 months prior to full study screening and considered to have a very low risk of recurrence, or

5. History of localized prostate cancer and receiving androgen deprivation therapy and considered to have a very low risk of recurrence.

6. Breast cancer: adequately treated lobular carcinoma in situ or ductal carcinoma in situ, or history of localized breast cancer and receiving antihormonal agents and considered to have a very low risk of recurrence

7. Other malignancy that is considered cured with minimal risk of recurrence

6. Stroke or seizure within 6 months prior to signing ICF.

7. Chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for participants suspected of having COPD and participants must be excluded if FEV1 is <50% of predicted normal.

8. Moderate or severe persistent asthma within the past 2 years or uncontrolled asthma of any classification. Note that participants who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate in the study.

9. Prior allogeneic bone marrow, hematopoietic stem cell or solid organ transplant.

10. Participant is pregnant, breast-feeding, or planning to become pregnant while enrolled in this study or within 90 days after the last dose of study treatment.

11. Participant plans to father a child while enrolled in this study or within 90 days after the last dose of study treatment.

12. Presence of the following cardiac conditions:

1. New York Heart Association stage III or IV congestive heart failure

2. Myocardial infarction or coronary artery bypass graft =6 months prior to randomization

3. History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration

4. History of severe non-ischemic cardiomyopathy

13. Any of the following:

1. Known to be seropositive for human immunodeficiency virus

2. Hepatitis B infection (ie, HBsAg or HBV-DNA positive). In the event the infection status is unclear, quantitative viral levels are necessary to determine the infection status.

3. Active hepatitis C infection as measured by positive HCV-RNA testing.

14. Major surgery within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment.

15. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 21 days prior to registration.

16. Contra indication or intolerance to required supportive care medications.

17. Concurrent medical or psychiatric condition or disease that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study, such as:

1. Uncontrolled diabetes

2. Acute diffuse infiltrative pulmonary disease

3. Evidence of active systemic viral, fungal, or bacterial infection, requiring systemic antimicrobial therapy

4. History of autoimmune disease with the exception of vitiligo, type I diabetes, and prior autoimmune thyroiditis that is currently euthyroid based on clinical symptoms and laboratory testing

5. Disabling psychiatric conditions (eg, alcohol or drug abuse), severe dementia, or altered mental status

6. Any other issue that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site, to understand informed consent or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

7. History of non-compliance with recommended medical treatments

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Dara-VRd intensification, Dara-R maintenance
Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort • MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance
• AHCT intensification, Dara-R maintenance
Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort • MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance
• AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance
Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
• AHCT intensification, Dara-R consolidation, Dara-R maintenance
Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
• Dara-VRd induction
Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone

Locations

Country	Name	City	State
United States	University of Alabama at Birmingham	Birmingham	Alabama

Sponsors (2)

Lead Sponsor	Collaborator
University of Alabama at Birmingham	Janssen Scientific Affairs, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Depth of response obtained with 6 cycles of Dara-VRd	For the primary objective "for all patients" to describe the depth of response obtained with 6 cycles of Dara-VRd and the corresponding endpoint of MRD negativity at end of induction all patients with MRD evaluable	6 months
Primary	Sustained MRD negativity	MRD <10-5 assessed before and after 13 cycles of maintenance	18 months
Secondary	Progression-free survival	Occurrence of disease progression or death	60 months
Secondary	Overall Survival	Occurrence of death regardless of cause	60 months
Secondary	Cumulative incidence of MRD resurgence or progression	Occurrence of MRD >= 10-5 or progression for patients starting observation with MRD surveillance (MRD-SURE) after achieving sustained MRD negativity.	60 months